Gratis Versand ab 16,99 €. Mehr Infos.
Bookbot

Combination Cancer Therapy

Autor*innen

Parameter

  • 292 Seiten
  • 11 Lesestunden

Mehr zum Buch

Expert physician-scientists and clinicians review those combinations of novel target agents classic chemotherapies that hold the most promise for the future of medical oncology, and detail their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. The combinations run the gamut of targeted therapies against cell surface receptors (EGF-R and HER2), the cell cycle (the CDKs), signal transduction events (PKC and NF-kB), apoptosis (bcl-2), as well as focused therapies in ovarian cancer, hematologic diseases, and breast cancer. The authors emphasize novel translational approaches that are rapidly moving from the laboratory bench top to the patient's bedside for the future treatments in cancer therapy.

Buchkauf

Combination Cancer Therapy, Gary K. Schwartz

Sprache
Erscheinungsdatum
2005
product-detail.submit-box.info.binding
(Hardcover)
Wir benachrichtigen dich per E-Mail.

Lieferung

  • Gratis Versand ab 16,99 € in ganz Deutschland! Mehr Infos.

Zahlungsmethoden

Keiner hat bisher bewertet.Abgeben

Titel
Combination Cancer Therapy
Sprache
Englisch
Autor*innen
Gary K. Schwartz
Erscheinungsdatum
2005
Einband
Hardcover
Seitenzahl
292
ISBN10
1588292002
ISBN13
9781588292001
Reihe
Beschreibung
Expert physician-scientists and clinicians review those combinations of novel target agents classic chemotherapies that hold the most promise for the future of medical oncology, and detail their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. The combinations run the gamut of targeted therapies against cell surface receptors (EGF-R and HER2), the cell cycle (the CDKs), signal transduction events (PKC and NF-kB), apoptosis (bcl-2), as well as focused therapies in ovarian cancer, hematologic diseases, and breast cancer. The authors emphasize novel translational approaches that are rapidly moving from the laboratory bench top to the patient's bedside for the future treatments in cancer therapy.